greg_yap-HEADSHOT

Greg Yap

Partner

Bio + Healthcare

Greg is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Since joining in 2017, Greg has led Menlo investments including Cartwheel, Clear Labs, Curie, Delfi, Encoded, Epiodyne, Genesis, H1, Koala, Ophelia, Particle, Pliant (PLRX), Riva, and Scribe. He has also been involved in Menlo’s investments in Benchling and Recursion (RXRX).

Previously, Greg was at Illumina Ventures as entrepreneur-in-residence, where he focused on new investments related to genomics. Prior to entering venture capital, Greg had 20 years of experience in senior executive and entrepreneurial roles in life science and digital health. He was CEO and co-founder of two startups: BlueLight Therapeutics (originally Biodesy), a structure-driven platform therapeutics company, and PyrAmes, a digital health remote monitoring company. At Roche Diagnostics/Ventana, Greg led a global market-leading cancer diagnostic assay business, serving 20 million patients and delivering $500 million in revenue annually. Greg’s operating experience also includes roles as the first healthcare entrepreneur-in-residence at GE; chief operating officer at Cellpoint Diagnostics, an early liquid biopsy startup; vice president and general manager for genetics and molecular diagnostics at Affymetrix, the microarray genomics pioneer; and consultant for McKinsey & Company.

Greg received his bachelor’s degree in molecular biology (summa cum laude) from Princeton University and his MBA from Stanford University’s Graduate School of Business. He is an Aspen Health Innovators Fellow and a member of the Aspen Global Leadership Network. Greg is a Bay Area native and has lived in 11 cities in the area. Greg serves on the board of Outward Bound California and loves all manner of outdoor activities with his family, including backpacking and snowboarding. His favorite sport is basketball.

Supported by: Lauren Etienne, lauren.etienne@menlovc.com

Greg is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Since joining in 2017, Greg has led Menlo investments including Cartwheel, Clear Labs, Curie, Delfi, Encoded, Epiodyne, Genesis, H1, Koala, Ophelia, Particle, Pliant (PLRX), Riva, and Scribe. He has also been involved in Menlo’s investments in Benchling and Recursion (RXRX).

Previously, Greg was at Illumina Ventures as entrepreneur-in-residence, where he focused on new investments related to genomics. Prior to entering venture capital, Greg had 20 years of experience in senior executive and entrepreneurial roles in life science and digital health. He was CEO and co-founder of two startups: BlueLight Therapeutics (originally Biodesy), a structure-driven platform therapeutics company, and PyrAmes, a digital health remote monitoring company. At Roche Diagnostics/Ventana, Greg led a global market-leading cancer diagnostic assay business, serving 20 million patients and delivering $500 million in revenue annually. Greg’s operating experience also includes roles as the first healthcare entrepreneur-in-residence at GE; chief operating officer at Cellpoint Diagnostics, an early liquid biopsy startup; vice president and general manager for genetics and molecular diagnostics at Affymetrix, the microarray genomics pioneer; and consultant for McKinsey & Company.

Greg received his bachelor’s degree in molecular biology (summa cum laude) from Princeton University and his MBA from Stanford University’s Graduate School of Business. He is an Aspen Health Innovators Fellow and a member of the Aspen Global Leadership Network. Greg is a Bay Area native and has lived in 11 cities in the area. Greg serves on the board of Outward Bound California and loves all manner of outdoor activities with his family, including backpacking and snowboarding. His favorite sport is basketball.

Supported by: Lauren Etienne, lauren.etienne@menlovc.com

Investments

Our Portfolio
benchling
benchling

Benchling is a life sciences R&D cloud platform helping the next generation of scientists make breakthrough discoveries faster than ever before.

Milestones
  • 2012 Founded
  • 2019 Partnered, Series C
benchling_graphic
delfi
delfi

Delfi is developing a revolutionary test for early detection of cancer using machine learning on DNA in the blood.

Milestones
  • 2019 Founded
  • 2019 Partnered, Seed
Partner
delfi_graphic
encoded_therapeutics-rectangle
encoded_therapeutics-rectangle

Encoded Therapeutics, a precision gene therapy company, is developing genomics-driven medicines that have the potential to transform the treatment paradigm for severe genetic disorders.

Milestones
  • 2014 Founded
  • 2019 Partnered, Series C
Partner
encoded_therapeutics_graphic
Genesis Therapeutics logo
Genesis Therapeutics logo

Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.

Milestones
  • 2019 Founded
  • 2020 Partnered, Series A
Partner
genesis_therapeutics_graphic

H1's health data platform supports the end-to-end therapeutic development process of medical companies and healthcare systems.

Milestones
  • 2017 Founded
  • 2020 Partnered, Series A

Ophelia is reinventing drug rehab by making evidence-based treatment private, affordable, and accessible via telemedicine.

Milestones
  • 2019 Founded
  • 2021 Partnered, Series A
ophelia_graphic
recursion NASDAQ: RXRX
recursion

Recursion is discovering transformative new treatments by combining automation, machine learning, and the world’s largest biological image datasets.

Milestones
  • 2013 Founded
  • 2017 Partnered, Series B
  • 2021 IPO; NASDAQ: RXRX
recursion_graphic
riva
riva

Riva Health provides a digital cardiology platform designed to give patients a comprehensive, equitable, and accessible way to manage hypertension and heart disease.

Milestones
  • 2013 Founded
  • 2017 Incubated by Menlo Labs
  • 2019 Seed
  • 2021 Series A
Partner
riva_health_graphic

Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies.

Milestones
  • 2015 IPO
Partner
Aimmune Therapeutics
Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies.
NASDAQ : AIMT

Benchling is a life sciences R&D cloud platform helping the next generation of scientists make breakthrough discoveries faster than ever before.

Milestones
  • 2012 Founded
  • 2019 Partnered, Series C
benchling_graphic
Benchling
Benchling is a life sciences R&D cloud platform helping the next generation of scientists make breakthrough discoveries faster than ever before.
benchling

Cartwheel is a tech-enabled provider for youth mental health services, helping schools and families tackle the student mental health crisis.

Milestones
  • 2022 Founded
  • 2023 Partnered, Series A
Partner
Cartwheel Care telehealth
Cartwheel
Cartwheel is a tech-enabled provider for youth mental health services, helping schools and families tackle the student mental health crisis.
Cartwheel Care logo

Clear Labs offers the only automated next-generation sequencing platform for applications including COVID diagnostics and food safety testing.

Milestones
  • 2014 Founded
  • 2018 Partnered, Series B
Partner
clear_labs_graphic
Clear Labs
Clear Labs offers the only automated next-generation sequencing platform for applications including COVID diagnostics and food safety testing.
clear_labs

Cofactor Genomics is a biotech company whose mission is to enable drug development, medical research, and personalized medicine using RNA-based information and technologies.

Milestones
  • 2008 Founded
  • 2017 Partnered, Series A
cofactor_genomics_graphic
Cofactor Genomics
Cofactor Genomics is a biotech company whose mission is to enable drug development, medical research, and personalized medicine using RNA-based information and technologies.
cofactor_genomics

Curie.Bio is a seed-stage venture firm and therapeutics accelerator focused on helping founders launch viable therapeutics companies.

Milestones
  • 2021 Founded
  • 2022 Partnered, Series A
Partner
Curie.Bio
Curie.Bio is a seed-stage venture firm and therapeutics accelerator focused on helping founders launch viable therapeutics companies.
curie

Delfi is developing a revolutionary test for early detection of cancer using machine learning on DNA in the blood.

Milestones
  • 2019 Founded
  • 2019 Partnered, Seed
Partner
delfi_graphic
Delfi Diagnostics
Delfi is developing a revolutionary test for early detection of cancer using machine learning on DNA in the blood.
delfi

Earli’s mission is to make cancer a benign experience, by catching and curing it early.

Milestones
  • 2018 Founded
  • 2021 Partnered, Series A
earli_graphic
Earli
Earli’s mission is to make cancer a benign experience, by catching and curing it early.
earli

Encoded Therapeutics, a precision gene therapy company, is developing genomics-driven medicines that have the potential to transform the treatment paradigm for severe genetic disorders.

Milestones
  • 2014 Founded
  • 2019 Partnered, Series C
Partner
encoded_therapeutics_graphic
Encoded Therapeutics
Encoded Therapeutics, a precision gene therapy company, is developing genomics-driven medicines that have the potential to transform the treatment paradigm for severe genetic disorders.
encoded_therapeutics-rectangle

Epiodyne is developing breakthrough opioid medicines to manage pain and treat opioid use disorder (OUD) with minimal potential for addiction and safety risks.

Milestones
  • 2016 Founded
  • 2018 Partnered, Series A
Partner
epiodyne_graphic
Epiodyne
Epiodyne is developing breakthrough opioid medicines to manage pain and treat opioid use disorder (OUD) with minimal potential for addiction and safety risks.
epiodyne

Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.

Milestones
  • 2019 Founded
  • 2020 Partnered, Series A
Partner
genesis_therapeutics_graphic
Genesis Therapeutics
Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.
Genesis Therapeutics logo

H1's health data platform supports the end-to-end therapeutic development process of medical companies and healthcare systems.

Milestones
  • 2017 Founded
  • 2020 Partnered, Series A
H1
H1's health data platform supports the end-to-end therapeutic development process of medical companies and healthcare systems.

Koala is a modern pet healthcare provider with a mail order pharmacy offering for pet medications.

Milestones
  • 2021 Founded
  • 2022 Partnered, Series A
Partner
koala_health_graphic
Koala Health
Koala is a modern pet healthcare provider with a mail order pharmacy offering for pet medications.
koala

Ophelia is reinventing drug rehab by making evidence-based treatment private, affordable, and accessible via telemedicine.

Milestones
  • 2019 Founded
  • 2021 Partnered, Series A
ophelia_graphic
Ophelia
Ophelia is reinventing drug rehab by making evidence-based treatment private, affordable, and accessible via telemedicine.

Particle Health is an API designed for healthcare innovators that gives access to vital medical data.

Milestones
  • 2017 Founded
  • 2020 Partnered, Series A
particle_health_graphic
Particle Health
Particle Health is an API designed for healthcare innovators that gives access to vital medical data.
Particle Health logo

Pliant Therapeutics is focused on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

Milestones
  • 2015 Founded
  • 2018 Partnered, Series B
  • 2020 IPO; NASDAQ: PLRX
Partner
pliant_therapeutics_graphic
Pliant Therapeutics
Pliant Therapeutics is focused on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
NASDAQ: PLRX

Recursion is discovering transformative new treatments by combining automation, machine learning, and the world’s largest biological image datasets.

Milestones
  • 2013 Founded
  • 2017 Partnered, Series B
  • 2021 IPO; NASDAQ: RXRX
recursion_graphic
Recursion
Recursion is discovering transformative new treatments by combining automation, machine learning, and the world’s largest biological image datasets.
NASDAQ: RXRX
recursion

Riva Health provides a digital cardiology platform designed to give patients a comprehensive, equitable, and accessible way to manage hypertension and heart disease.

Milestones
  • 2013 Founded
  • 2017 Incubated by Menlo Labs
  • 2019 Seed
  • 2021 Series A
Partner
riva_health_graphic
Riva Health
Riva Health provides a digital cardiology platform designed to give patients a comprehensive, equitable, and accessible way to manage hypertension and heart disease.
riva

Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying causes of genetic disorders.

Milestones
  • 2018 Founded
  • 2021 Partnered, Series B
Partner
scribe_therapeutics_graphic
Scribe Therapeutics
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying causes of genetic disorders.
scribe_therapeutics

Led by pioneers in synthetic biology and computation, Senti is pioneering new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies.

Milestones
  • 2016 Founded
  • 2018 Partnered, Series A
  • 2022 IPO; NASDAQ: SNTI
Partner
senti_bio_graphic
Senti Biosciences
Led by pioneers in synthetic biology and computation, Senti is pioneering new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies.
NASDAQ: SNTI

Vilya is creating a novel class of medicines to treat disease targets inside cells, leveraging its proprietary AI engine to design for drug-like properties and ultimately generate new drug candidates.

Milestones
  • 2022 Founded
  • 2023 Partnered, Series A
Partner
Vilya
Vilya is creating a novel class of medicines to treat disease targets inside cells, leveraging its proprietary AI engine to design for drug-like properties and ultimately generate new drug candidates.
Vilya logo

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease.

Milestones
  • 2023 → Founded
  • 2024 → Partnered, Seed + Series A
Partner
Xaira Therapeutics
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease.